Analysts Set Expectations for BCYC Q1 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Equities research analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Bicycle Therapeutics in a report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($0.87) per share for the quarter. B. Riley currently has a “Neutral” rating and a $17.00 target price on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share. B. Riley also issued estimates for Bicycle Therapeutics’ Q2 2025 earnings at ($0.91) EPS and Q3 2025 earnings at ($0.96) EPS.

Other equities analysts have also issued research reports about the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Stephens restated an “equal weight” rating and set a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. JMP Securities dropped their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Bicycle Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $29.14.

Bicycle Therapeutics Stock Performance

NASDAQ BCYC opened at $10.47 on Tuesday. Bicycle Therapeutics has a fifty-two week low of $10.38 and a fifty-two week high of $28.67. The stock’s fifty day moving average is $13.19 and its two-hundred day moving average is $19.27. The firm has a market capitalization of $722.91 million, a P/E ratio of -3.18 and a beta of 0.93.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.10. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm’s revenue for the quarter was down 30.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.16) earnings per share.

Institutional Investors Weigh In On Bicycle Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Assetmark Inc. acquired a new position in Bicycle Therapeutics in the third quarter valued at $34,000. Barclays PLC lifted its stake in shares of Bicycle Therapeutics by 878.3% during the fourth quarter. Barclays PLC now owns 2,612 shares of the company’s stock worth $37,000 after purchasing an additional 2,345 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in shares of Bicycle Therapeutics during the fourth quarter worth about $57,000. China Universal Asset Management Co. Ltd. increased its position in shares of Bicycle Therapeutics by 30.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock worth $131,000 after acquiring an additional 2,191 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after acquiring an additional 1,782 shares during the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Insider Activity

In related news, CAO Travis Alvin Thompson sold 2,686 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $15.00, for a total value of $40,290.00. Following the completion of the transaction, the chief accounting officer now directly owns 32,146 shares of the company’s stock, valued at $482,190. This trade represents a 7.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 985,397 shares of the company’s stock in a transaction on Friday, December 13th. The shares were bought at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the transaction, the director now directly owns 9,537,643 shares of the company’s stock, valued at $131,237,967.68. This represents a 11.52 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 27,677 shares of company stock valued at $392,413 in the last three months. 8.50% of the stock is currently owned by company insiders.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.